drugset / Trial / NCT05158062
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial is a multicenter, single-arm, phase II study evaluating the efficacy of pembrolizumab and bevacizumab in combination with platinum-based chemotherapy (PBC) followed by pembrolizumab, bevacizumab and olaparib as a maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.This study is planned to enroll eligible 35 patients from multiple study sites in Japan.
Timeline
- Start
- 2022-04-20
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Olaparib | Small molecule | 300 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Docetaxel | Small molecule | 60 mg/m2 | — |
| Background | Docetaxel | Small molecule | 70 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |